Search

Displaying results 2381 - 2390 of 10000 in total
  1. Drug

    Acetic acid

    go.drugbank.com/drugs/DB03166
    ApprovedInvestigational

    (Stedman, 26th ed) Acetic acid otic (for the ear) is an antibiotic that treats infections caused by bacteria or fungus.

    Mixtures: Acid Concentrate D-18006, Acid Concentrate D-18003Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Palifosfamide

    go.drugbank.com/drugs/DB05668
    Investigational

    Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.

  3. Drug

    GPI-1485

    go.drugbank.com/drugs/DB05814
    Investigational

    GPI 1485 is being studied in phase 2 clinical trials for the treatment of Parkinson's disease and post-prostatectomy erectile dysfunction and in pre-clinical development for HIV related dementia and neuropathy … In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without affecting normal, healthy nerves.

  4. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition

  5. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein. … [A260256] DMD tends to be more prevalent in males.

  6. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. … Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.

  7. Drug

    Eflornithine

    go.drugbank.com/drugs/DB06243
    ApprovedInvestigationalWithdrawn

    [A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric … a 68% reduction in the risk of death were observed.

  8. Drug

    Moxisylyte

    go.drugbank.com/drugs/DB09205
    Approved

    Moxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist. … [L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s.

    Categories: Drugs Used in Erectile Dysfunction
  9. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … [A214280, A214295] On January 16, 2024, inebilizumab also received Health Canada approval for the same indication.

  10. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    [A241065] Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation. … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.